RGTL.F Panoramica delle azioni Argent BioPharma Limited, una società multidisciplinare di sviluppo di farmaci, è impegnata nella fornitura di medicinali per l'immunologia e la neurologia in tutto il mondo. Maggiori dettagli
Analisi del rischio + 2 più rischi
Vedi tutti gli assegni di rischio Catturate i vostri pensieri, i link e la narrativa aziendale
Argent BioPharma Limited Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Argent BioPharma Prezzi storici delle azioni Prezzo attuale dell'azione AU$0.12 Massimo di 52 settimane AU$0.57 Minimo di 52 settimane AU$0.12 Beta 1.1 Variazione di 1 mese -67.60% Variazione a 3 mesi -49.30% Variazione di 1 anno -65.32% Variazione a 3 anni -99.58% Variazione a 5 anni -99.53% Variazione dall'IPO -99.71%
Notizie e aggiornamenti recenti
Argent Biopharma Limited Appoints Daniel Robinson as Director Nov 28 Argent BioPharma Limited has completed a Follow-on Equity Offering in the amount of AUD 0.2 million. Oct 28
Argent BioPharma Limited has filed a Follow-on Equity Offering in the amount of AUD 0.2 million. Oct 24
Argent BioPharma Limited, Annual General Meeting, Nov 28, 2024 Sep 25 Argent BioPharma Provides Update on Proposed Delisting from the Australian Securities Exchange Sep 23
Argent BioPharma Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million. Vedi altri aggiornamenti
Argent Biopharma Limited Appoints Daniel Robinson as Director Nov 28 Argent BioPharma Limited has completed a Follow-on Equity Offering in the amount of AUD 0.2 million. Oct 28
Argent BioPharma Limited has filed a Follow-on Equity Offering in the amount of AUD 0.2 million. Oct 24
Argent BioPharma Limited, Annual General Meeting, Nov 28, 2024 Sep 25 Argent BioPharma Provides Update on Proposed Delisting from the Australian Securities Exchange Sep 23
Argent BioPharma Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.
Argent Biopharma Limited Announces the Appointment of Mr. Igor Bluvstein as Chief Financial Officer May 08
Argent BioPharma Limited Announces Appointment of Shlomo Sadoun to the Advisory Board Apr 16 MGC Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 0.74 million. Jan 10
MGC Pharmaceuticals Limited's Product Artemic Receives FDA Approval in Saudi Arabia Dec 19
MGC Pharmaceuticals Limited Announces Board Changes Dec 01 MGC Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 12.4 million. Nov 08
MGC Pharmaceuticals Limited, Annual General Meeting, Nov 30, 2023 Oct 09
MGC Pharmaceuticals Limited Announces Positive Pre-Clinical Trial Results on CimetrA® Aug 15
MGC Pharmaceuticals Limited Announces Executive Changes Jul 30
MGC Pharmaceuticals Limited Announces Resignation of Arron Canicais, Joint Company Secretary Jul 29 MGC Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of £0.65 million. Jul 15
MGC Pharmaceuticals Limited Announces Appointment of Layton Mills as Non-Executive Director
MGC Pharmaceuticals Limited Announces Board Changes, Effective 1 June 2023 May 30
MGC Pharmaceuticals Limited Announces Change of CFO Feb 03
MGC Pharmaceuticals Ltd Completes the Pre-Clinical Rodent Studies on Cimetratm Jan 10
MGC Pharmaceuticals Limited Announces Resignation of Evan Hayes as Director Jan 03
MGC Pharmaceuticals Limited Announces Completion of CimetrA Efficacy Pre-Clinical Trial Dec 09
Mgc Pharmaceuticals Ltd Announces the Results of the Open Label Clinical Study, a White Label Version of ArtemiCTM Support Oct 25
MGC Pharmaceuticals Limited Provides an Update on Its Operations Oct 20
MGC Pharmaceuticals Limited, Annual General Meeting, Nov 24, 2022 Oct 18
Mgc Pharmaceuticals Limited Announces Board Changes Oct 05
MGC Pharmaceuticals Successfully Developed Herbal-Inspired Products for Treatment of Long Covid and Covid-19 Sep 23
MGC Pharmaceuticals Limited Announces Interim Results from the Data Collected from the Initial 16 Patients Participating in the CimetrA Dose Finding Study Sep 21
MGC Pharmaceuticals Limited, Annual General Meeting, Oct 05, 2022 Sep 05
MGC Pharmaceuticals Ltd Provides the Following Results from A Recently Completed Randomised, Double Blind, Placebo Controlled Study Investigating the Effect of MGC's Pharma's Epilepsy Treatment, Cannepil®, on Vehicle Driving Performance, Sedation and Mood (Trial) Aug 15 MGC Pharmaceuticals Limited announced that it expects to receive AUD 10 million in funding from Mercer Street Capital Partners, LLC Jul 30
Mgc Pharmaceuticals Ltd Announces Appointment of Mr. Robert Clements as Chief Commercial Officer Jul 19
MGC Pharmaceuticals Limited Announces Long COVID Study Results for Artemic Support Jul 15
MGC Pharmaceuticals Limited Receives Approval Granted for the Dose Finding Study of CimetrA on Patients Diagnosed With Covid-19 Jul 08
MGC Pharmaceuticals Limited Announces the Launch of ZAM- Medical Data App in Collaboration with Caba Tech Jul 06
MGC Pharmaceuticals Limited Announces CimetrA Pre-Clinical Trial Progress Report Jun 28
Mgc Pharmaceuticals Limited Announces Cimetra Clinical Trial Progress Jun 24
MGC Pharmaceuticals Ltd Has Completes Successful In-Vitro Preclinical Research Study into the Use of Cannabinoids to Treat Glioblastoma Multiforme Cells, A Fast-Growing and Aggressive Form of Brain Cancer Jun 16
Mgc Pharmaceuticals Ltd to Provide Details of the Results of Its Phase II Clinical Trial into the Effect of Its Proprietary Investigational Medicinal Product, CogniCann Jun 06
MGC Pharmaceuticals Ltd Patent Application forCannEpil®Drug Delivery System Patent granted by European IP Office May 12
Mgc Pharmaceuticals Limited Announces Appointment of Angela-Marie Graham as Its New London Based Chief Financial Officer Apr 26
MGC Pharmaceuticals Ltd Announces Patent Application for CimetrATM Approve by European IP Office Apr 21
MGC Pharmaceuticals Limited Announces Executive Changes Apr 12
MGC Pharmaceuticals Ltd Receives an Import Approval Permit for the Importation of ArtemiCTM Rescue into India Jan 07
Swiss PharmaCan Ag Announces Start of Clinical Trial with Glow LifeTech and MGC Pharmaceuticals to Confirm Treatment Potential of Artemic Support in Long Covid Patients Dec 22
MGC Pharmaceuticals Limited announced that it has received £5.5 million in funding Dec 02
MGC Pharmaceuticals Limited announced that it expects to receive AUD 10.3 million in funding Dec 01
MGC Pharmaceuticals Limited Announces Uk Import Permit Granted for Cannepil Sep 15
MGC Pharmaceuticals Limited Announces Successful Submission of Self-Nano Emulsifying Cannabinoids-Ionic Complex Concentrate Drug Delivery System Jul 15
Mgc Pharmaceuticals Limited Announces Phase Iii Cimetra Clinical Trial Commences Jul 14
MGC Pharmaceuticals Limited Announces Cannabis Derived Epilepsy Investigational Medicinal Product Jun 15
Mgc Pharmaceuticals Ltd Provides Progress Report on Major Clinical Trial Programs Planned for 2021 May 25
MGC Pharmaceuticals Ltd Announces Further Results from the Phase II Clinical and Preclinical Studies on ArtemiC(TM) May 08
MGC Pharmaceuticals Limited Revives Increased Initial Supply Agreement for ArtemiC Mar 04
MGC Pharmaceuticals Ltd Signs Master Suppy and Distribution Agreement with Swiss PharmaCan AG for Artemic Rescue Feb 18
MGC Pharmaceuticals Limited Announces New In-Vitro Cannabinoid Study on Glioblastoma Treatment Feb 16
Swiss Pharmacan AG, and MGC Pharma Report on Successful Phase II Clinical Results For COVID-19 Treatment Candidate Based on its MyCell Technology Jan 15
MGC Pharmaceuticals Ltd Appoints Nicole Godresse as Its New Global Chief Sales Officer Jan 13
MGC Pharmaceuticals Limited Announces ArtemiC Phase II Clinical Trial Results Dec 16
MGC Pharmaceuticals Limited Appoints Narelle Warren as Joint Company Secretary, Effective 30 November 2020 Nov 30
MGC Pharmaceuticals Limited (ASX:MXC) completed the acquisition of Clinical assets of Medicinal Cannabis Clinic Pty Ltd. Nov 24
MGC Pharma Progresses Successful Results from Cannabinoid Treatment of Glioblastoma Towards Clinical Trials Nov 18
MGC Pharmaceuticals Limited Announces Completion of Phase Ii Clinical Trial on Covid-19 Patients Nov 06
MGC Pharmaceuticals Limited Announces Affordable Cannabinoid Product Line Oct 20
MGC Pharmaceuticals Limited Announces the Results of A Pre-Clinical in Vivo Safety and Toxicity Study Oct 16
MGC Pharmaceuticals Ltd Announces It Has Completed the First Shipments of Its Mercury Pharma Line Which Includes the High THC Ratio Products Directly Oct 13
MGC Pharmaceuticals Limited Launches CannEpil App Oct 08
MGC Pharmaceuticals Limited announced that it expects to receive AUD 15 million in funding from Mercer Street Capital Partners, LLC Oct 06
MGC Pharmaceuticals Limited Auditor Raises 'Going Concern' Doubt Oct 04
MGC Pharmaceuticals Limited (ASX:MXC) signed a binding term sheet to acquire Clinical assets of Medicinal Cannabis Clinic Pty Ltd for AUD 1.4 million. Oct 02
MGC Pharmaceuticals Limited (ASX:MXC) completed the acquisition of an additional 6.67% stake in PANAX Pharma s.r.o. Sep 09 Rendimenti per gli azionisti RGTL.F US Pharmaceuticals US Mercato 7D 0% 1.6% -2.2% 1Y -65.3% 9.7% 23.9%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: RGTL.F ha avuto una performance inferiore rispetto al US Pharmaceuticals che ha registrato un rendimento 9.7 % nell'ultimo anno.
Rendimento vs Mercato: RGTL.F ha avuto una performance inferiore al mercato US che ha registrato un rendimento 23.9 % nell'ultimo anno.
Volatilità dei prezzi Is RGTL.F's price volatile compared to industry and market? RGTL.F volatility RGTL.F Average Weekly Movement n/a Pharmaceuticals Industry Average Movement 10.4% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.0% 10% least volatile stocks in US Market 3.1%
Prezzo delle azioni stabile: Il prezzo delle azioni di RGTL.F è stato volatile negli ultimi 3 mesi.
Volatilità nel tempo: Dati insufficienti per determinare la variazione della volatilità di RGTL.F nell'ultimo anno.
Informazioni sull'azienda Argent BioPharma Limited, una società multidisciplinare di sviluppo di farmaci, è impegnata nella fornitura di medicinali per l'immunologia e la neurologia a livello mondiale. I principali prodotti candidati dell'azienda includono CimetrA, in fase di sperimentazione clinica IIB per il trattamento delle lesioni polmonari acute e dell'ARDS; CannEpil, in fase di sperimentazione clinica I per l'epilessia refrattaria; e CogniCann, in fase di sperimentazione clinica IIA per il trattamento sintomatico della demenza e dell'Alzheimer. L'azienda è inoltre impegnata nello sviluppo preclinico di Irnican per il trattamento del glioblastoma multiforme e di RGAI03MW01, che si concentra sul trattamento delle ferite croniche.
Mostra di più Argent BioPharma Limited Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di Argent BioPharma con la sua capitalizzazione di mercato? RGTL.F statistiche fondamentali Capitalizzazione di mercato US$5.08m Guadagni(TTM ) -US$10.94m Ricavi(TTM ) US$556.20k
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) RGTL.F Conto economico (TTM ) Ricavi AU$891.08k Costo del fatturato AU$1.20m Profitto lordo -AU$304.15k Altre spese AU$17.23m Guadagni -AU$17.53m
Ultimi guadagni dichiarati
Jun 30, 2024
Prossima data di guadagno
n/a
Utile per azione (EPS) -0.32 Margine lordo -34.13% Margine di profitto netto -1,967.34% Rapporto debito/patrimonio netto -149.0%
Come si è comportato RGTL.F nel lungo periodo?
Vedi performance storica e confronto
Analisi aziendale e situazione dei dati finanziari Dati Ultimo aggiornamento (ora UTC) Analisi dell'azienda 2024/12/24 01:29 Prezzo dell'azione a fine giornata 2024/12/02 00:00 Guadagni 2024/06/30 Guadagni annuali 2024/06/30
Fonti dei dati I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC . I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
Pacchetto Dati Tempistica Esempio Fonte USA * Dati finanziari della società 10 anni Conto economico Rendiconto finanziario Bilancio Stime di consenso degli analisti +3 anni Previsioni finanziarie Obiettivi di prezzo degli analisti Prezzi di mercato 30 anni Prezzi delle azioni Dividendi, scissioni e azioni Proprietà 10 anni Top azionisti Insider trading Gestione 10 anni Team di leadership Consiglio di amministrazione Sviluppi principali 10 anni
* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui .
Modello di analisi e Snowflake I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github ; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube .
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .
Fonti analitiche Argent BioPharma Limited è coperta da 4 analisti. 0 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
Analista Istituzione Salvatore Gaetano Verdoliva Canaccord Genuity Robin Davison Capital Network by Proactive Investors Maxim Jacobs Edison Investment Research
Mostra 1 altri analisti 
